| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 319245 | European Neuropsychopharmacology | 2007 | 10 Pages |
AimsTo compare olanzapine and risperidone outcome on some neurocognitive dimensions in chronic schizophrenia patients with prominent negative symptoms.MethodWe randomised and followed for 1 year 235 chronic schizophrenia outpatients with a SANS global score ≥ 10 to open-label flexible-dose treatment with olanzapine or risperidone. Clinical, functional and cognitive assessments [including the COGLAB battery reaction time, vigilance-span of apprehension (VSA) and a card-sorting task] were done periodically.ResultsThere were no significant differences between olanzapine (n = 120) and risperidone (n = 115) treatments in the neurocognitive dimensions tested. Mean ± SD doses were 12.2 ± 5.8 mg/day of olanzapine and 4.9 ± 2.0 mg/day of risperidone. Patients in the olanzapine group showed a significant improvement in the VSA total score, but the within-group change was modest (effect size of 0.26); the difference with the risperidone group was not significant (p = 0.207). Patients in both groups showed a significant improvement in a composite measure of executive efficiency based on the card-sorting task, with within-group effect size of 0.21 (risperidone) and 0.35 (olanzapine); the between-group difference was not significant (p = 0.164). At baseline, better functional status correlated with VSA. Patients scoring lower on VSA or executive efficiency at baseline improved more on these respective measures.ConclusionModest pro-cognitive effects can also be found in chronic schizophrenia outpatients with prominent negative symptoms when treated with olanzapine or risperidone.
